Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selim Kuci

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
International Journal of Oncology|November 8, 2005
Hypericin: a promising fluorescence marker for differentiating between glioblastoma and neurons in vitroRainer Ritz, Martin Müller, Michael Weller, et al.
Annals of the New York Academy of Sciences|June 12, 2003
Biology and plasticity of CD133+ hematopoietic stem cellsRupert Handgretinger, Paul R Gordon, Thasia Leimig, et al.
Annals of the New York Academy of Sciences|June 12, 2003
CDCP1 is a novel marker for hematopoietic stem cellsTim Conze, Reiner Lammers, Selim Kuci, et al.
British Journal of Haematology|December 17, 2003
Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donorsPeter Lang, Peter Bader, Michael Schumm, et al.
Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology|November 7, 2007
Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize hematopoietic chimerism-high informativity and sensitivity as well as excellent reproducibility and precision of measurementAndre Willasch, Gaby Schneider, Britta Sofia Reincke, et al.
International Archives of Medicine|August 17, 2011
Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric casesCaroline M Wernicke, Thomas Gp Grunewald, Juenger Hendrik, et al.
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
International Journal of Oncology|November 8, 2005
Hypericin: a promising fluorescence marker for differentiating between glioblastoma and neurons in vitroRainer Ritz, Martin Müller, Michael Weller, et al.
Annals of the New York Academy of Sciences|June 12, 2003
Biology and plasticity of CD133+ hematopoietic stem cellsRupert Handgretinger, Paul R Gordon, Thasia Leimig, et al.
Annals of the New York Academy of Sciences|June 12, 2003
CDCP1 is a novel marker for hematopoietic stem cellsTim Conze, Reiner Lammers, Selim Kuci, et al.
British Journal of Haematology|December 17, 2003
Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donorsPeter Lang, Peter Bader, Michael Schumm, et al.
Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology|November 7, 2007
Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize hematopoietic chimerism-high informativity and sensitivity as well as excellent reproducibility and precision of measurementAndre Willasch, Gaby Schneider, Britta Sofia Reincke, et al.
International Archives of Medicine|August 17, 2011
Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric casesCaroline M Wernicke, Thomas Gp Grunewald, Juenger Hendrik, et al.
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Pageof 1